Breelyn A. Wilky, MD, of the Sylvester Comprehensive Cancer Center, Miami, Fl, discusses the success of some of the recent trials in sarcoma research. She talks about 2 studies using checkpoint inhibitors which are now in expansion phases, due to successful initial results, to help even more patients gain access to the treatments. These studies look at the combination of ipilimumab and nivolumab (NCT02500797) and the other, pembrolizumab and SARC 028 (NCT02301039), the pivotal study for monotherapy for sarcoma patients. Furthermore, Dr Wilky talks about another more recent trial she is involved in, with axitinib and pembrolizumab (NCT02636725). She explains that recruitment for this trial has been completed and preliminary data is expected in November. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.
